| Pair Name | Kaempferol, Erlotinib | ||
| Phytochemical Name | Kaempferol (PubChem CID: 5280863 ) | ||
| Anticancer drug Name | Erlotinib (PubChem CID: 176870 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Kaempferol, Erlotinib | |||
| Disease Info | [ICD-11: 2C10] | Pancreatic cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Down-regulation | Phosphorylation | EGFR | hsa1956 | |
| Down-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Expression | PIK3CA | hsa5290 | |
| In Vitro Model | PANC-1 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0480 |
| BxPC-3 | Pancreatic ductal adenocarcinoma | Homo sapiens (Human) | CVCL_0186 | |
| In Vivo Model | The in vivo results revealed that treatment combination of KAE and ERL further reduced the volume and weight of subcutaneous grafted tumors. | |||
| Result | These data imply that KAE may be a valid therapeutic candidate to potentiate PC cell sensitivity to ERL via inhibiting PI3K/AKT and EGFR signaling. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor. Inflammopharmacology. 2021 Oct;29(5):1587-1601. doi: 10.1007/s10787-021-00848-1. | Click |
